These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7224738)

  • 1. Gram-negative bacteremias. Analysis of factors for clinical assessment of gentamicin resistance.
    Lynch JM; Hodges GR; Clark GM; Dworzack DL
    Arch Intern Med; 1981 Apr; 141(5):582-6. PubMed ID: 7224738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin treatment of pulmonary infections involving gentamicin-resistant gram-negative bacilli.
    Bartlett JG
    Am J Med; 1977 Jun; 62(6):945-8. PubMed ID: 868911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.
    Valdivieso M; Bodey GP
    Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled comparison of amikacin and gentamicin.
    Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS
    N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefoxitin resistance in community-acquired gram-negative bacillary bacteremia. Associated clinical risk factors.
    McCue JD
    Arch Intern Med; 1985 May; 145(5):834-6. PubMed ID: 3873228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gentamicin resistance among gram-negative bacillary blood isolates in a hospital with long-term use of gentamicin.
    Mylotte JM
    Arch Intern Med; 1987 Sep; 147(9):1642-4. PubMed ID: 3307673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results.
    Daikos GK; Kosmidis JC; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S286-90. PubMed ID: 993623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms.
    Yu VL; Rhame FS; Pesanti EL; Axline SG
    JAMA; 1977 Aug; 238(9):943-7. PubMed ID: 328950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside.
    King JW; White MC; Todd JR; Conrad SA
    Clin Infect Dis; 1992 Apr; 14(4):908-15. PubMed ID: 1576287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects].
    Romoli E; Di Leonardo F; Giordano G; De Felice M; Cerquetti F; Vonmoos A
    Minerva Urol; 1981; 33(2):85-90. PubMed ID: 7322100
    [No Abstract]   [Full Text] [Related]  

  • 16. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
    Moellering RC; Wennersten C; Kunz LJ; Poitras JW
    Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic resistance patterns during aminoglycoside restriction.
    Young EJ; Sewell CM; Koza MA; Clarridge JE
    Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amikacin therapy for serious gram-negative bacillary infections.
    Meyer RD; Lewis RP; Carmalt ED; Finegold SM
    Ann Intern Med; 1975 Dec; 83(6):790-800. PubMed ID: 1200524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.
    Drasar FA; Farrell W; Maskell J; Williams JD
    Br Med J; 1976 Nov; 2(6047):1284-7. PubMed ID: 1000196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.